Suppr超能文献

配体密度控制 C 型凝集素样分子-1 受体特异性摄取聚合物纳米颗粒。

Ligand Density Controls C-Type Lectin-Like Molecule-1 Receptor-Specific Uptake of Polymer Nanoparticles.

机构信息

University of Rochester, Department of Biomedical Engineering, Rochester, NY, USA.

University of Rochester Medical Center, Department of Orthopaedics and Center for Musculoskeletal Research, Rochester, NY, USA.

出版信息

Adv Biosyst. 2020 Nov;4(11):e2000172. doi: 10.1002/adbi.202000172. Epub 2020 Oct 19.

Abstract

The newest generation of drug delivery systems (DDSs) exploits ligands to mediate specific targeting of cells and/or tissues. However, studies investigating the link between ligand density and nanoparticle (NP) uptake are limited to a small number of ligand-receptor systems. C-type lectin-like molecule-1 (CLL1) is uniquely expressed on myeloid cells, which enables the development of receptors specifically targeting treat various diseases. This study aims to investigate how NPs with different CLL1 targeting peptide density impact cellular uptake. To this end, poly(styrene-alt-maleic anhydride)-b-poly(styrene) NPs are functionalized with cyclized CLL1 binding peptides (cCBP) ranging from 240 ± 12 to 31 000 ± 940 peptides per NP. Unexpectedly, the percentage of cells with internalized NPs is decreased for all cCBP-NP designs regardless of ligand density compared to unmodified NPs. Internalization through CLL1 receptor-mediated processes is further investigated without confounding the effects of NP size and surface charge. Interestingly, high density cCBP-NPs (>7000 cCBP per NP) uptake is dominated by CLL1 receptor-mediated processes while low density cCBP-NPs (≈200 cCBP per NP) and untargeted NP occurred through non-specific clathrin and caveolin-mediated endocytosis. Altogether, these studies show that ligand density and uptake mechanism should be carefully investigated for specific ligand-receptor systems for the design of targeted DDSs to achieve effective drug delivery.

摘要

新一代药物传递系统(DDS)利用配体来介导细胞和/或组织的特异性靶向。然而,关于配体密度与纳米颗粒(NP)摄取之间关系的研究仅限于少数配体-受体系统。C 型凝集素样分子-1(CLL1)在髓样细胞上特异性表达,这使得能够开发专门针对各种疾病的受体。本研究旨在研究具有不同 CLL1 靶向肽密度的 NP 如何影响细胞摄取。为此,聚(苯乙烯-共-马来酸酐)-b-聚(苯乙烯)NP 用环化的 CLL1 结合肽(cCBP)功能化,cCBP 的密度范围从每个 NP 240±12 到 31000±940 个肽。出乎意料的是,与未修饰的 NP 相比,所有 cCBP-NP 设计的内化 NP 的细胞百分比都降低了,无论配体密度如何。在不干扰 NP 大小和表面电荷影响的情况下,进一步研究了通过 CLL1 受体介导的过程进行内化。有趣的是,高密度 cCBP-NP(>7000 个 cCBP/ NP)摄取主要由 CLL1 受体介导的过程主导,而低密度 cCBP-NP(≈200 个 cCBP/ NP)和非靶向 NP 则通过非特异性网格蛋白和 caveolin 介导的内吞作用发生。总之,这些研究表明,对于特定的配体-受体系统,应该仔细研究配体密度和摄取机制,以设计靶向 DDS,从而实现有效的药物传递。

相似文献

本文引用的文献

1
Nanoparticles in the clinic: An update.临床中的纳米颗粒:最新进展
Bioeng Transl Med. 2019 Sep 5;4(3):e10143. doi: 10.1002/btm2.10143. eCollection 2019 Sep.
5
Targeting CLL-1 for acute myeloid leukemia therapy.针对 CLL-1 进行急性髓系白血病治疗。
J Hematol Oncol. 2019 Apr 24;12(1):41. doi: 10.1186/s13045-019-0726-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验